Stemson is going to use minipigs in the next stage of their hair cloning research
- Thread starter werefckd
- Start date
The main thesis of HMI is endometriosis, not hairloss. So comparing them with Stemson is not an apple vs apple situation.
The total amount raised by Stemson (22.5M) is the absolute record for a company focused on treating only hairloss and the second place is not even close.
And I don’t think HMI is snake oil, I just don’t believe (yet) that the treatment will yield the magnitude of results you guys are so sure about.
Nice example, people thought that the amount Samumed raised was going to be used to develop hairloss treatments lol
Geoff in his last interview somewhat indicated that because of the nature of their procedure they wouldn’t be able to benefit from the fast track regulations. But it’s too early to know, maybe they will find a workaround on it.
No idea, seems like they are still evaluating the options
Incorrect
Where you raise money matters. Sammumed was always a scam, making wild claims in the media to take stupid people's money. HMI raised 56 million before anyone even heard of them. All they had to do was show the data, they didn't have to pump
Well we can check that on their company website under the “about” section…
oooops
anyways it’s obvious that their priority is treating that women’s disease, no point in arguing with that.
Yes surely this is due to their Androgenetic Alopecia approach and not the cancer, tumor or cartilage regeneration.
- Reaction score
- 1,335
Lol. Nice sarcasm. I love it.
Their largest investor is Qiming who specializes in biotech and has experts to assess the potential of drug candidates. Samumed got most of their money from firms who were out of their expertise and don't know any better.
Last edited:
According to the founder of the company they have already applied for approval to begin phase 2 for Androgenetic Alopecia.
- Reaction score
- 1,335
It's amazing how many times we have to repeat the same thing for people to start noticing it.
- Reaction score
- 179
whenthey derive the dermal papilla cells from embroynic stem cells most of then become the cell types they desire, going via the route of ipcs and then over neural crest to dermal papilla there is a significant amount of cells that do not commit properly and thus cannot produce viable hair growth. the concept works as is evident in the fact that some cells do become aome kind of DP cells that expresses the right genes ans acts properly however some do not. theyare working on improving this process so they can have highef yields because this is a very delicate process and cells are living things with manx variables that can go wrong, IPC research is quite new and very expensive.
so the latter is correct. the prpblem is not proliferating some kind of cells but that some do not respond once implanted. i think it was about 90% for embrypnic stem cells and 50% for ipcs? so half the cells they derive are garbage. mightbe wrong here its been a while since i read it. they wrote a paper on this and you can find it on their website
"Heqirui is committed to the research, development and commercialization of the first innovative drugs, targeting the widespread male and female diseases, with the goal of improving the quality of life. At present, Heqirui Pharmaceutical Co., Ltd. has announced the completion of Series A financing and has signed a global exclusive license agreement with Bayer AG for the development and industrialization of monoclonal antibodies targeting the prolactin (PRL) receptor. In accordance with the license agreement, Heqirui Medicine will develop and industrialize a new antibody targeting the prolactin (PRL) receptor globally based on Bayer's intellectual property rights. Potential indications for this antibody include male and female pattern alopecia, endometriosis, and other chronic diseases.Lol and do you think Hopemed got $56 million dollar for their AA prolactin treatment? There isn't a lot of difference with samumed.
The focus of Hopemed isn't balding.
From press release:
HopeMed focuses on the three major disease areas of women's health, endocrine, and cardiovascular diseases
Hope Medicine completed US$56 million in Series B financing, strengthening capabilities of global innovation
SHANGHAI, May 6, 2021 /PRNewswire/ -- Recently, the global innovative drug R&D company Hope Medicine Inc. (referred to as "HopeMed") announced the completion of a Series B...www.asiaone.com
Prolactin (PRL) receptor antibody is a monoclonal antibody that targets the prolactin receptor, blocking the signaling pathway downstream of prolactin in a non-competitive manner. The mode of administration is subcutaneous injection. The antibody showed good tolerability in phase I clinical trials (including single-dose and multiple-dose administration). At the same time, studies have found that this antibody can effectively promote the hair growth of elderly red-faced monkeys. After 6 months of treatment, the number of terminal hairs in the alopecia area has nearly doubled, even in areas that were almost completely bald before, and the effect has continued to reach More than two years after stopping the drug. This research is the result of close cooperation between Bayer and Peking University Institute of Molecular Medicine scientists, and it is expected to be used in the treatment of male and female alopecia in the future."
和其瑞医药联合创始人肖瑞平：医药强国，吾辈使命 - 创新人才 - 南京生物医药谷
· 和其瑞医药有限公司联合创始人、董事长兼首席执行官；· 北京大学讲席教授，北大分子医学研究所所长；· 《新英格兰医学期刊》副主编
www.njbpv.cn
I see hair loss mentioned first and in greater detail than the brief mention of endometriosis, which they never even bothered to try in macaques apparently.
This article has been revised unfortunately, but the initial print of it included quotes from Xiao Rui-Ping stating that Bayer was developing the drug for endometriosis, but they noticed it significantly increased the length of hair in mice. Xiao Rui-Ping was running the IMM in China, which has a NHP(non-human primate) facility. She was already working with Bayer on other things so she asked them if she could test the drug on her macaques for hair loss. When she saw the hair growth on the macaques she convinced Bayer to license the drug to her, and then created HMI. If it wasn't for the hair growth in macaques then HMI wouldn't even exist, so I don't know how you guys can think that it's not their primary indication. The only reason phase I was for endo is because it was Bayer's primary indication for the drug. If not for hair loss indication Bayer would have kept development in-house. They licensed it because they knew the hair loss indication would be profitable, but it didn't fit their pipeline. It is literally the only indication for which they KNOW the drug is effective. I expect Phase 2 trials to begin recruiting soon. You don't have to take my word for all this, many other people saw the original interview that was removed, and can backup what I'm saying. In every interview she talks about hair loss. The only mention of endometriosis is ever, "it can be used for endometriosis too".
Last edited:
This would be good. Do you have a link?
- Reaction score
- 984
Thank you very much For making this effort to Write about Hope Medicine’s Intention.
hopefully they will Start trials soon otherwise i Hope they will give an interview or article that we we Are able to Look in their timeline and plans.
Do You think it is possible For an European to Travel to USA and participate in the trials??
I would Go there and live For 1-2 years For the trial in US